Skip to content

Comparing Two Treatments to Improve Movement and Reduce Jaundice in Premature Babies

Comparative Efficacy Of Vojta Versus Multimodal Stimulation On Neuromotor Behavior And Bilirubin Levels Among Preterm With Neonatal Jaundice: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104590
Enrollment
40
Registered
2026-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P590- Neonatal jaundice associated withpreterm delivery

Interventions

Intervention1: Vojta Therapy: Preterm neonates with neonatal jaundice will receive Vojta therapy along with standard medical care. The intervention will be administered by a trained pediatric physioth

Sponsors

Datta Meghe Institute of Higher Education & Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Gestational Age: Preterm Infants born at less than equal to 37 weeks of gestation. Age of enrolment: Infants diagnosed with Neonatal Jaundice within the first 7 days. Bilirubin Levels: Infants with Elevated bilirubin levels requiring intervention, as determined by clinical guidelines. Parental Consent: Written informed Consent obtained from parents or legal guardians. Neurological status: Infants without congenital neurological abnormality, but at risk for neuromotor impairment due to prematurity

Exclusion criteria

Exclusion criteria: Severe Medical Conditions: Infants with severe congenital anomalies or genetic disorders. Other Treatments: Infants receiving other forms of physical therapy or interventions that could affect neuromotor outcomes. Severe Jaundice: Infants requiring exchange transfusion or intensive phototherapy beyond standard care. Neurological Abnormalities: Infants diagnosed with major neurological conditions (e.g., hypoxic-ischemic encephalopathy, intracranial haemorrhage). Infection: Infants with active infections or sepsis that might interfere with the study protocol

Design outcomes

Primary

MeasureTime frame
APGARTimepoint: Baseline day, 4Day,7 Day.

Secondary

MeasureTime frame
INFANIB Bilirubin level Length of NICU stay and hospital stay Timepoint: Baseline day, 4Day,7 Day.

Countries

India

Contacts

Public ContactYukta Ghugal

Ravi Nair Physiotherapy College

sharathhullumani@gmail.com8660621272

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026